Welcome to our dedicated page for Legend Biotech Corporation news (Ticker: $LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Legend Biotech Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Legend Biotech Corporation's position in the market.
Legend Biotech (NASDAQ: LEGN) reported first quarter 2024 financial results with CARVYKTI® net trade sales of $157 million, FDA label expansion, and a milestone payment of $45 million. The company's cash position stands at $1.3 billion, ensuring financial stability until 2026. Legend Biotech's recent developments include increased manufacturing capacity, regulatory approvals in the U.S., Europe, and Brazil, and a Master Manufacturing and Supply Services Agreement with Novartis. The company's ESG report aligns with SASB standards, and the collaboration revenue has shown significant growth.